Our Immune Medicine Platform
Translating the brilliance
of the adaptive immune system
The immune system is astonishingly brilliant in its ability to precisely detect and attack disease and to record its activity throughout our lives. Our team has created a powerful platform to make the elegant complexity of the immune system accessible to researchers and clinicians around the world to allow each and every person’s immune system tell its own story. Our immune medicine platform applies our proprietary technologies, computational biology, software and machine learning to read the diverse genetic code of a patient’s immune system and understand precisely how it detects and treats disease in that patient.
Revealing the enormous diversity and scale of the adaptive immune system
The key cells of the adaptive immune system that enable our body to mount responses against antigens are called T cells and B cells. Each of these cells has a unique receptor (T cell receptors and B cell receptors, or TCRs and BCRs) which can recognize one or a small number of the millions of antigens to which our bodies are continuously exposed.
Quantifying TCRs & BCRs
immunoSEQ sequences single chains of “Y-shaped” T cell receptors or B cell receptors using next-generation sequencing (NGS), enabling us to understand the quantity and diversity of T and B cells in a biological sample. This provides deep insights into individual and collective immune responses at a scale that is thousands of times greater than was previously possible.
Mapping TCRs to antigens
MIRA (Multiplexed Identification of T cell Receptor Antigen Specificity) maps millions of TCRs to thousands of clinically relevant antigens. Combined with immunoSEQ, MIRA elucidates what potential diseases a patient’s immune system has seen or is actively fighting.
Pairing receptor chains
pairSEQ builds on immunoSEQ by using a combinatorial strategy to accurately pair the alpha and beta chains of T-cell receptors at high-throughput, which is challenging to do at scale using other methods because the two chains of the Y-shaped receptors are located on different chromosomes.
Identifying optimal therapeutic TCRs
TruTCR characterizes binding, cytotoxicity, and safety properties of antigen-specific, paired TCRs to identify a subset that is therapeutic-grade, enabling the discovery and development of optimal clinical candidates to be engineered into TCR-mediated cellular therapies.
immunoSEQ, MIRA, pairSEQ, and TruTCR are for Research Use Only. Not for use in diagnostic procedures.
Clinical Immunomics Database
Data informs clinical applications
The massive amount of data generated by our immune medicine platform is stored in our dynamic clinical immunomics database of over 30 billion immune receptors. The application of machine learning, in collaboration with Microsoft, exponentially accelerates the growth of novel insights from this database, which drives our ability to rapidly discover and develop potential diagnostic and therapeutic applications.
Explore the hundreds of articles, published in peer-reviewed journals, using our proprietary immune profiling platform across cancer, autoimmune conditions, infectious diseases and other disease areas.
Find publications by Adaptive as well as our collaborators and partners who leverage our technologies.
FEATURED RESEARCH PUBLICATION
Nature Medicine | Papers | October 2018
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resect- able melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monother- apy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers.